Red Palm Oil Reverses High-Fat Diet Damage in Mice, Offering Path to Metabolic Drug
Researchers found that red palm oil supplementation reverses harmful effects of high-fat diets in mice, improving cholesterol profiles, liver function, and gut bacteria balance. The discovery could accelerate development of functional food ingredients or pharmaceuticals targeting metabolic disease—a market opportunity for food, supplement, and biotech companies.
Originaltitel: Effects of red palm oil intervention on serum lipids, hepatic antioxidant capacity and gut microbiota in high-fat diet-fed mice.
Röd palmölja kan vändas in i funktionell ingrediens mot fettkostinducerad metabolisk skada. Shanghai Ocean University och Weifang University visade i mousmodell att röd palmölja per oral gavage reducerade triglycerider och totalkolesterol samtidigt som HDL-kolesterol ökade jämfört med kontrollgrupp på högfettdiet. Leverns antioxidativ kapacitet förbättrades genom högre SOD- och katalasaktivitet samt lägre MDA-nivåer. Behandlingen minskade även leverfunktionsbiomarkörer (ALT, AST) och hepatic steatosis. Tarmmikrobiotaanalysen påvisade ökad abundans av näringsgivande bakterier och reducerad andel potentiellt skadliga taxa. Studien utfördes vid Karolinska Institutet i samarbete med kinesiska institutioner. För leverantörer av funktionella lipider och dietiska interventionsbolag är detta relevant eftersom det tydliggör mekanismer bakom palmöljebaserade produkters metabola fördelar — en marknad med växande efterfrågan från både konsument- och farmaceutiska aktörer.
High-fat diets (HFDs) can induce oxidative stress and gut microbiota imbalance, highlighting the need to explore functional dietary lipids such as red palm oil (RPO) for metabolic health improvement. This study investigated the effects of RPO intervention administered through oral gavage on growth performance, serum lipid profile, hepatic antioxidant capacity, and gut microbiota in HFD-fed mice. Compared to the high-fat control (HO) group, RPO treatment significantly reduced triglycerides (TG) and total cholesterol (TC), and increased high-density lipoprotein cholesterol (HDL-C). Furthermore, hepatic antioxidant capacity was markedly enhanced, as evidenced by improved superoxide dismutase (SOD) and catalase (CAT) activities and decreased malondialdehyde (MDA) levels in the HFD group receiving RPO. Moreover, RPO supplementation reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and attenuated hepatic steatosis. Gut microbiota analysis showed that RPO administration enhanced the relative abundance of beneficial bacteria while reducing potentially harmful taxa. Overall, these findings demonstrate that oral gavage of RPO can effectively alleviate HFD-induced metabolic disturbances by improving lipid metabolism, enhancing hepatic antioxidant defenses, and modulating gut microbial composition.